Novo Nordisk Foundation Cellerator A/S
Public limited companyCVR 44450569Kongens LyngbyActive
Novo Nordisk Foundation Cellerator A/S is a public limited company, based in Kongens Lyngby, active in research and experimental development on natural sciences and engineering, founded in 2023. The company made a loss in both 2024 and 2025, most recently DKK 13.1m. With 33 employees, the company is about 7 times larger than the industry median. Equity grew to DKK 346.5m in 2025.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- The loss grew: from DKK 9.3m to DKK 13.1m (2024 → 2025).
- Equity rose 73% (2024 → 2025), to DKK 346.5m.
Employees
- 16 more employees than a year earlier: 33 (07/2026) against 17 (07/2025).
Management and owners, last 24 months
- New in management: Trine Haastrup (board member, 23/12/2025).
- Stepped down: Søren Nedergaard (board member, 23/12/2025) and Erika Johanna Söderberg Johnsson (board member, 23/12/2025).
Registrations, last 24 months
- 30/09/2026: Name changed from Novo Nordisk Foundation Cellerator P/S to Novo Nordisk Foundation Cellerator A/S
- 19/12/2025: Share capital changed from 401,000 DKK to 56,401,000 DKK
- 18/06/2025: Moved to Nordvej 250A, 2800 Kongens Lyngby
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2024–2025 · amounts in DKK thousandEquity and net profit
| 2024 | 2025 | Change | |
|---|---|---|---|
| Revenue | not stated | not stated | – |
| Gross profit | −10,780 | 3,903 | +136.2% |
| Operating profit (EBIT) | −10,780 | – | – |
| Net profit | −9,277 | −13,054 | −40.7% |
| Total assets | 241,884 | 392,344 | +62.2% |
| Equity | 200,514 | 346,460 | +72.8% |
| Liabilities | 41,370 | 45,884 | +10.9% |
| Cash and cash equivalents | 78,427 | 36,444 | −53.5% |
| Average number of employees | 0 | 15 | – |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresLoss for 2 years in a row
Net result has been negative in 2024–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
2 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 15/04/2026 | The company | PDF not statedXBRL |
| 2024 | 23/11/2023 – 31/12/2024 | 08/07/2025 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with 20–49 employees9,922 companies in the comparison | No. 8,238of 9,892 Better than 17% | No. 135of 9,922 Better than 99% |
| Same industry and 20–49 employees64 companies in the comparison | No. 37of 62 Better than 41% | No. 2of 64 Better than 98% |
| Companies that are founded within the last five years16,662 companies in the comparison | No. 2,993of 16,614 Better than 82% | No. 92of 16,661 Better than 99% |
| All companies of type A/S18,025 companies in the comparison | No. 12,843of 17,786 Better than 28% | No. 947of 18,024 Better than 95% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- Novo Nordisk Foundation Cellerator A/SDKK 3.9m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Novo Nordisk Foundation Cellerator A/S−DKK 13.1m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- Novo Nordisk Foundation Cellerator A/SDKK 346.5m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- Novo Nordisk Foundation Cellerator A/S33
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Novo Nordisk Fonden100%
Management
4 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Thomas Hassing Ronøe Carlsen | Director | 23/11/2023 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Pelle Kristoffer Munk-Poulsen | Board member | 23/11/2023 |
| Mads Krogsgaard Thomsen | Chair of the board | 23/11/2023 |
| Trine Haastrup | Board member | 23/12/2025 |
- Founders
- Novo Nordisk Fonden, NNF General Partner ApS
Former management (2)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Søren Nedergaard | Board member | 23/11/2023 | 23/12/2025 |
| Erika Johanna Söderberg Johnsson | Board member | 23/11/2023 | 23/12/2025 |
Signing rule: Selskabet tegnes af enten formanden for bestyrelsen i forening med ét medlem af bestyrelsen eller af formanden for bestyrelsen i forening med en direktør.
Address and production units
2 active production unitsNordvej 250A
2800 Kongens Lyngby
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Novo Nordisk Foundation Cellerator A/S | Nordvej 250A, 2800 Kongens Lyngby | 36 | 1029859058 |
| Cellerator Laboratorium BII | Ole Maaløes Vej 3, 2200 København N | – | 1032868556 |
Purpose
Selskabets formål er at drive virksomhed inden for udvikling af celleterapi til forskning og klinisk brug samt at drive anden i forbindelse hermed stående virksomhed.
The purpose is quoted from the register in Danish.
Changes year by year
17 registered events20262 changesname 1 · accounts 1
- NameName changed from Novo Nordisk Foundation Cellerator P/S to Novo Nordisk Foundation Cellerator A/S
- AccountsAnnual report for 2025 published
20257 changesmanagement 3 · capital 1 · accounts 1 · address 1 · industry 1
- ManagementTrine Haastrup appointed board member
- ManagementSøren Nedergaard stepped down as board member
- ManagementErika Johanna Söderberg Johnsson stepped down as board member
- CapitalShare capital changed from 401,000 DKK to 56,401,000 DKK
- AccountsAnnual report for 2024 published
- AddressMoved to Nordvej 250A, 2800 Kongens Lyngby
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20241 changecapital 1
- CapitalShare capital changed from 400,000 DKK to 401,000 DKK
20237 changesfounded 1 · management 5 · ownership 1
- FoundedRegistered as Novo Nordisk Foundation Cellerator P/S
- ManagementSøren Nedergaard appointed board member
- ManagementErika Johanna Söderberg Johnsson appointed board member
- ManagementPelle Kristoffer Munk-Poulsen appointed board member
- ManagementMads Krogsgaard Thomsen appointed chair of the board
- ManagementThomas Hassing Ronøe Carlsen appointed director
- OwnershipNOVO NORDISK FONDEN registered as owner (100%)
Related companies
Same industry in Lyngby-Taarbæk
- Thales Aerospace Communications Lyngby ApS52 employees
- Immudex ApS35 employees
- Capres A/S34 employees
- Mdsi ApS33 employees
- Bifrost Communications ApS9 employees
- Mycoverse ApS9 employees
Same people in management
- Novo Nordisk A/Svia Mads Krogsgaard Thomsen
- Servier Symphogen A/Svia Mads Krogsgaard Thomsen
- Life A/Svia Søren Nedergaard
- Quantum Foundry Copenhagen A/Svia Mads Krogsgaard Thomsen
- BII Holdings A/Svia Mads Krogsgaard Thomsen
- Oticon Medical A/Svia Pelle Kristoffer Munk-Poulsen
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.